Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 May;71(5):904–906. doi: 10.1038/bjc.1995.176

Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.

M F Pera 1, B Köberle 1, J R Masters 1
PMCID: PMC2033767  PMID: 7734313

Abstract

Metastatic testicular germ cell tumours are cured in approximately 85% of patients using cisplatin-based combination chemotherapy. Patients who fail to respond have a poor prognosis, and there is a need for more effective treatments for cisplatin-resistant disease. In this study, it is shown that two of four cell lines derived from human non-seminomatous testicular germ cell tumours are exceptionally sensitive to temozolomide, a new imidazotetrazine which can cross the blood-brain barrier in mice. In addition, three pairs of cisplatin-resistant sublines show little cross-resistance to temozolomide. These data suggest that temozolomide might have activity against non-seminomatous testicular germ cell tumours which have relapsed following cisplatin-containing chemotherapy, and could have a role in the treatment of patients with metastatic lesions in the brain.

Full text

PDF
904

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bronson D. L., Andrews P. W., Solter D., Cervenka J., Lange P. H., Fraley E. E. Cell line derived from a metastasis of a human testicular germ cell tumor. Cancer Res. 1980 Jul;40(7):2500–2506. [PubMed] [Google Scholar]
  2. Bubeník J., Baresová M., Viklický V., Jakoubková J., Sainerová H., Donner J. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer. 1973 May;11(3):765–773. doi: 10.1002/ijc.2910110327. [DOI] [PubMed] [Google Scholar]
  3. Hogan B., Fellous M., Avner P., Jacob F. Isolation of a human teratoma cell line which expresses F9 antigen. Nature. 1977 Dec 8;270(5637):515–518. doi: 10.1038/270515a0. [DOI] [PubMed] [Google Scholar]
  4. Horwich A., Wilson C., Cornes P., Gildersleve J., Dearnaley D. Increasing the dose intensity of chemotherapy in poor-prognosis metastatic non-seminoma. Eur Urol. 1993;23(1):219–222. doi: 10.1159/000474597. [DOI] [PubMed] [Google Scholar]
  5. Kelland L. R., Mistry P., Abel G., Freidlos F., Loh S. Y., Roberts J. J., Harrap K. R. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res. 1992 Apr 1;52(7):1710–1716. [PubMed] [Google Scholar]
  6. Masters J. R., Hepburn P. J., Walker L., Highman W. J., Trejdosiewicz L. K., Povey S., Parkar M., Hill B. T., Riddle P. R., Franks L. M. Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res. 1986 Jul;46(7):3630–3636. [PubMed] [Google Scholar]
  7. Masters J. R., Osborne E. J., Walker M. C., Parris C. N. Hypersensitivity of human testis-tumour cell lines to chemotherapeutic drugs. Int J Cancer. 1993 Jan 21;53(2):340–346. doi: 10.1002/ijc.2910530228. [DOI] [PubMed] [Google Scholar]
  8. Newlands E. S., Blackledge G. R., Slack J. A., Rustin G. J., Smith D. B., Stuart N. S., Quarterman C. P., Hoffman R., Stevens M. F., Brampton M. H. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992 Feb;65(2):287–291. doi: 10.1038/bjc.1992.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Pera M. F., Blasco Lafita M. J., Mills J. Cultured stem-cells from human testicular teratomas: the nature of human embryonal carcinoma, and its comparison with two types of yolk-sac carcinoma. Int J Cancer. 1987 Sep 15;40(3):334–343. doi: 10.1002/ijc.2910400309. [DOI] [PubMed] [Google Scholar]
  10. Pera M. F., Friedlos F., Mills J., Roberts J. J. Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloroplatinum(II) on DNA. Cancer Res. 1987 Dec 15;47(24 Pt 1):6810–6813. [PubMed] [Google Scholar]
  11. Raina V., Singh S. P., Kamble N., Tanwar R., Rao K., Dawar R., Rath G. K. Brain metastasis as the site of relapse in germ cell tumor of testis. Cancer. 1993 Oct 1;72(7):2182–2185. doi: 10.1002/1097-0142(19931001)72:7<2182::aid-cncr2820720719>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  12. Rasheed S., Gardner M. B., Rongey R. W., Nelson-Rees W. A., Arnstein P. Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses. J Natl Cancer Inst. 1977 Apr;58(4):881–890. doi: 10.1093/jnci/58.4.881. [DOI] [PubMed] [Google Scholar]
  13. Walker M. C., Masters J. R., Margison G. P. O6-alkylguanine-DNA-alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines. Br J Cancer. 1992 Nov;66(5):840–843. doi: 10.1038/bjc.1992.370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Walker M. C., Parris C. N., Masters J. R. Differential sensitivities of human testicular and bladder tumor cell lines to chemotherapeutic drugs. J Natl Cancer Inst. 1987 Aug;79(2):213–216. [PubMed] [Google Scholar]
  15. Walker M. C., Povey S., Parrington J. M., Riddle P. N., Knuechel R., Masters J. R. Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines. Eur J Cancer. 1990;26(6):742–747. doi: 10.1016/0277-5379(90)90133-e. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES